{"schema_version":"secwatch.filing_event.v1","accession":"0001714899-22-000143","form_type":"8-K","ticker":"DNLI","cik":"0001714899","company_name":"Denali Therapeutics Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.852622+00:00","generated_at":"2026-06-22T09:30:16.346615+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Denali Q3 net loss widens to $103.3M; cash at $1.11B after $296M offering","bullets":["Net loss of $103.3M for Q3 2022 vs. $84.6M in Q3 2021; collaboration revenue fell to $3.6M from $5.3M.","R&D expenses rose to $87.8M (up $16.2M) driven by LRRK2 milestone payment and pipeline progress.","Cash, cash equivalents, and marketable securities totaled $1.11B as of Sep 30, 2022, plus net proceeds of $296.2M from Oct 2022 public offering.","Phase 3 LIGHTHOUSE study of BIIB122 initiated in LRRK2-positive Parkinson's; Phase 2 COMPASS study of DNL310 enrolling in Hunter syndrome.","Interim Phase 1 data for TAK-594/DNL593 showed substantial CSF progranulin increases supporting FTD-GRN Part B dosing."],"urls":{"canonical":"https://secwatch.observer/filing/0001714899-22-000143","json":"https://secwatch.observer/filing/0001714899-22-000143.json","markdown":"https://secwatch.observer/filing/0001714899-22-000143.md","text":"https://secwatch.observer/filing/0001714899-22-000143.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000143/0001714899-22-000143-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000143/dnli-20221103.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:30:16.346615+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f0c60130dbda4b0baf9add4669ac56d74a348f6a","claim":"Denali Therapeutics Inc. reported the third quarter ended September 30, 2022 results: net income net loss of $103.3 million.","evidence_excerpt":"Denali Therapeutics Inc. (the \"Company\") issued a press release announcing its financial results for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1714899/000171489922000143/0001714899-22-000143-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Net income","value":"net loss of $103.3 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}